At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progre CheckMate 274 investigators compared adjuvant nivolumab with placebo (PBO) in patients with MIUC ...
Adjuvant nivolumab improves DFS in MIBC patients, regardless of prior neoadjuvant chemotherapy, with a median DFS of 25.6 months versus 8.5 months with placebo. Overall survival rates at 24 and 36 ...
Among patients with muscle-invasive urothelial carcinoma (MIUC), the presence of detectable circulating tumor DNA (ctDNA) after surgery may identify those who are likely to benefit from adjuvant ...
Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer. Patients with high-risk muscle-invasive urothelial ...
Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus ...
SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to updated ...
Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study. This is an ASCO ...
Longer follow-up from the CheckMate 274 trial shows nivolumab given after radical surgery for high-risk muscle-invasive urothelial carcinoma maintains a clinically meaningful improvement in ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx immunohistochemical assay to extend the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results